Inhibitory effect of somatostatin on basal and vasoactive intestinal peptide-stimulated cyclic AMP production and cyclic AMP-dependent protein kinase activity in HeLa cells  by Prieto, Juan C.
Volume 144, number 1 FEBS LETTERS July 1982 
Inhibitory effect of somatostatin on basal and vasoactive intestinal 
peptide-stimulated cyclic AMP production and cyclic AMP-dependent 
protein kinase activity in HeLa cells 
Juan C. Prieto 
Departamento de Bioquimica, Facultad de Medicina, Alcalri de Henares, Madrid, Spain 
Received 27 May 1982 
1. INTRODUCTION 
Both vasoactive intestinal peptide (VIP) and 
somatostatin are present in central nervous system 
as well as in specialized cells or nerves which are 
located in close proximity to the endocrine or exo- 
crine cells on which they are presumed to act [ 1,2]. 
Therefore the notion has arisen that these peptides 
may act together or separately with a dual role as 
paracrine or neurocrine agents on target tissues. 
of great importance in cellular processes uch as the 
cell cycle and development associated with growth, 
proliferation, differentiation and hypertrophy of 
cells. 
2. MATERIALS AND METHODS 
Procedures for growth in culture, collection and 
washing of HeLa cells have been described in 
[ 17,181. 
It is well accepted that the interaction of VIP with 
target cells induces a cascade of events, including 
the activation of adenylate cyclase [1,3-71 and 
cyclic AMP-dependent protein,kinase [8,9]. On the 
contrary, the involvement of the cyclic AMP system 
in the mechanism of action of somatostatin has 
been questioned [ 101 I]. Nevertheless, the inhibitory 
role of somatostatin on cyclic AMP production 
[ 12- 141 and cyclic AMP-dependent protein kinase 
[ 15,161 has been shown in a variety of cell prepara- 
tions. 
Cyclic AMP production was studied as in [17]. 
The incubation medium (0.5 ml final vol.) consisted 
of 35 mM Tris-HCl buffer (pH 7.5), 50 mM NaCl, 
1.4% (w/v) bovine serum albumin, 1 mg bacitra- 
tin/ml, 0.2 mM 3-isobutyl- 1 -methylxauthini 
(IBMX) and, when indicated, somatostatin and/or 
VIP. The addition of 2 X lo5 cells/ml was followed 
by 45 min incubation at 15°C. Then, 2.5 ml meth- 
anol was added and, after centrifugation, the 
supernatant was evaporated and cyclic AMP deter- 
mined by a protein binding assay [2 11. 
To understand further the molecular mechanism 
of somatostatin action, we have simultaneously 
studied here the effect of this peptide on cyclic AMP 
production and cyclic AMP-dependent protein 
kinase activity in HeLa cells. This malignant cell line 
derives from a human carcinoma of the uterine 
cervix and possesses high-affinity binding sites for 
VIP and a VIP-dependent adenylate cyclase system 
[ 171 coupled to cyclic AMP-dependent protein 
kinase [ 181. We have also determined the antagon- 
istic relationship between VIP and somatostatin on 
the regulation of both cyclic AMP production and 
cyclic AMP-dependent protein kinase, 2 parameters 
Experiments on cyclic AMP-dependent protein 
kinase activity were conducted as in [ 181. The assay 
was performed in the same medium as above, sup- 
plemented with 5 mM MgC12 (0.25 ml final vol), at 
the indicated concentrations of somatostatin and/ 
or VIP. The reaction was initiated by the addi- 
tion of lo6 cells/ml followed by 15 min incubation 
at 15°C. Then, 0.1 ml cold Triton X-100 (0.4%) 
in 35 mM Tris-HCl buffer (pH 7.5) was added. 
After sonication the lysate was centrifuged at 10 000 
x g for 2 min. Protein kinase activity in the result- 
ing supematant was determined as in [22] and ex- 
pressed as activity ratio, i.e., the activity determined 
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without added cyclic AMP ( - ) vs the activity de- 
termined in the presence of an excess (10 -5 M) of 
cyclic AMP ( + ). 
Values are mean + SEM. Statistical analysis was 
carried out by Student’s z-test. Synthetic somato- 
statin and VIP were from Peninsula Labs; bacitra- 
tin, bovine serum albumin and cyclic AMP from 
Sigma; and IBMX from Aldrich. 
3. RESULTS 
As expected, VIP stimulated cyclic AMP pro- 
duction in HeLa cells in a dose-dependent manner 
(tig.1). Half-maximal stimulation was observed at 
2.5 + 0.3 nM VIP and maximal stimulation (3.5 
times above basal level) at > 10 nM peptide. 
Somatostatin, at 1 PM, significantly inhibited 
basal and VIP-stimulated cyclic AMP levels (fig. 1) 
at 0.1-300 nM added VIP. In this condition, half- 
maximal stimulation of cyclic AMP production was 
elicited by 1.9 k 0.3 nM VIP (not significantly 
different from the value obtained in the absence of 
somatostatin), and maximal stimulation was again 
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Fig. 1. Ability of increasing doses of VIP to stimulate cy- 
clic AMP production in the absence (0) or presence (o) of 
1 PM somatostatin. Each point is the mean + SEM of 3 
expt, each performed in triplicate. When comparing both 
curves, differences were statistically significant @ < 0.05 
or lower) throughout the whole range of VIP concentra- 
tions as well as in the absence of this peptide. 
Fig.2. Ability of increasing doses of somatostatin to inhi- 
bit cyclic AMP levels in the absence (0) or presence (o) of 
30 nM VIP. Each point is the mean + SEM of 3 expt, 
each performed in triplicate. Somatostatin at 2 1 PM 
elicited a statistically significant @ < 0.05) inhibition of 
either basal or VIP-stimulated cyclic AMP levels. 
Table 1 
Effects of VIP and somatostatin on cyclic AMP- 
dependent protein kinase activity 
Specific activity ratio 
(- cyclic AMP/ + cyclic AMP) 
Basal 0.51 &O.Ol 
30 nM VIP 0.82? 0.07 
1 PM Somatostatin 0.47 2 0.02 
+ 30 nM VIP 0.60 + 0.06 
HeLa cells (lo6 cells/ml) were incubated at 15°C for 15 
min in 0.25 ml medium containing either no effector, 
VIP, somatostatin or both peptides. Results are the mean 
+ SEM (n = 4) of the protein kinase activity ratio, each 
assay being made in triplicate without and with IO PM 
cyclic AMP. Differences with respect to basal value are 
all statistically significant @ < 0.05 or lower) 
inhibited by 40% at 1 PM somatostatin whereas the 
increment produced by a maximally effective VIP 
concentration was reduced by 60%. 
0 9 8 7 6 5 
174 
Volume 144, number 1 FEBS LETTERS July 1982 
The inhibitory effect of somatostatin was dose- 
dependent (l&.2). Both basal and VIP (30 nM)- 
stimulated cyclic AMP production were progress- 
ively inhibited by increasing concentrations of soma- 
tostatin, significant decreases being first observed 
at 1 PM. We did not test somatostatin doses > 3 PM. 
The ability of somatostatin to inhibit cyclic 
AMP-dependent protein kinase in HeLa cells is 
shown in table 1. A slight but significant effect on 
basal activity could be defined. Furthermore, 1 PM 
somatostatin inhibited by 60% the increase in the 
activity ratio elicited by 30 nM VIP. 
4. DISCUSSION 
These data demonstrate asomatostatin i duction 
in HeLa cells of decreased cyclic AMP levels related 
to other cellular signals such as cyclic AMP-depen- 
dent protein kinase activity in basal as well as in 
VIP-stimulated conditions. Furthermore, these re- 
sults suggest hat HeLa cells must have specific re- 
ceptors for somatostatin. However, it is not clear 
whether this peptide acts by first interacting with a 
membrane site or after penetrating into the cell. In 
fact, peptides of the size of somatostatin or larger 
can enter into cells [23]. 
The observed inhibitory effect of somatostatin on 
cyclic AMP production in HeLa cells appears to be 
related to a decreased activity of adenylate cyclase 
more than to an increased activity of cyclic nucleo- 
tide phosphodiesterase. In fact, experiments were 
performed in the presence of a concentration of 
phosphodiesterase inhibitor that blocks the action 
of the enzyme in this cell preparation [171. 
These results indicate that somatostatin antagon- 
izes the known [ 17,181 stimulatory effect of VIP on 
cyclic AMP production and cyclic AMP-dependent 
protein kinase activity in HeLa cells. Somatostatin 
appears to impair the efficiency (the magnitude of 
the induced stimulation) of VIP on adenylate 
cyclase without altering the potency (referred to the 
concentration of effector used) of this peptide. In 
fact, half-maximal stimulation of cyclic AMP pro- 
duction was observed at a similar VIP concentration 
both in the absence or presence of somatostatin. 
Furthermore, the observed inhibitory effect of 
somatostatin alone on cyclic AMP levels as well as 
oncyclicAMP-dependentproteinkinaseactivitycan- 
not explain the results obtained in the simultaneous 
presence of VIP and somatostatin. 
With respect o the biological significance of the 
action of VIP and somatostatin in HeLa cells, it 
remains a matter of conjecture. Since proliferation 
and differentiation of cells appear to be related to 
cyclic AMP levels, cyclic AMP-dependent protein 
kinase activity and protein phosphorylation [ 19,201, 
HeLa cells provide a valuable model to study the 
role of both peptides in such processes. In another 
context, it should be remembered that these malig- 
nant cells derive from the epithelium of the uterine 
cervix, a site where VIP and somatostatin have been 
identified as neuropeptides [24]. Then, they could 
be liberated in situ at high levels and participate in 
the local regulation of some physiological functions. 
Studies on normal cells should permit to learn the 
modifications of somatostatin and VIP actions 
during the malignant transformation as well as 
the involvement of both peptides in functions of the 
genito-urinary tract. 
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